Impact of Antistaphylococcal Penicillins and Cefazolin on the Emergence of Resistance in French Hospitals
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 644
- 试验地点
- 1
- 主要终点
- Association between the cefazolin/antistaphylococcal penicillins consumptions and the resistant bacteria emergence
研究概览
简要总结
Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.
研究设计
- 研究类型
- Observational
- 观察模型
- Ecologic Or Community
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •French hospitals which have collected their consumption and resistance data on the French national database named CONSORES (From 2019 to 2022)
排除标准
- 未提供
结局指标
主要结局
Association between the cefazolin/antistaphylococcal penicillins consumptions and the resistant bacteria emergence
时间窗: Between the first january 2018 and the 31st december 2022
The total consumption of antibiotics (expressed as number of Defined Daily Doses (DDD) per 1000 inhabitants per day) will be correlate with the resistant bacteria emergence (only incidence for each bacterial strain)
次要结局
- Factors associated with the emergence of resistant bacteria(Between the first january 2018 and the 31st december 2022)
- Factors associated with the consumption of antibiotics(Between the first january 2018 and the 31st december 2022)
- Evolution of resistance in French hospitals(Between the first january 2018 and the 31st december 2022)
- Evolution of antibiotics consumption in French hospitals(Between the first january 2018 and the 31st december 2022)
研究者
LEFEVRE Benjamin
Doctor in the field of infectious diseases (MD PhD)
Central Hospital, Nancy, France